

Plasma C1 inhibitor (C1-INH) was determined in 64 patients with different malignant diseases and in 58 healthy persons. Cl-INH antigen concentration was measured by radial immunodiffusion (RID), whereas its functional activity was assayed with chromogenic substrate. Within-run and day-to-day precision of both methods were good, with CVs ranging from 3.6 to 5.4%. Plasma C1-INH antigen concentrations were significantly higher in the patients than in healthy controls (P=4.0 x 10-3), as were their C1-INH functional activities (P=3.5 x 10-3). C1-INH activities obtained in the patient plasma samples were in correlation with their antigen concentrations (r = 0.914), showing that C1-INH synthesized in malignant disease was functional. However, the specific activity of the C1-INH (functional activity/antigen concentration ratio) was significantly lower in the patient group as compared with the controls (P=2.1 x 10-6), indicating partial inactivation of plasma C1-INH in malignant diseases. The C1-INH specific activity in patients was inversely proportional to its antigen concentration.
| EMTREE drug terms: | antigenchromogenic substratecomplement component C1s inhibitor |
|---|---|
| EMTREE medical terms: | articlecancer cellconcentrationcontrolled studyfemalefunctional assessmenthumanhuman tissueimmunodiffusionleukemialymphomamajor clinical studymalemalignant neoplastic diseaseplasmaplasmacytomapriority journalsolid tumor |
complement component C1s inhibitor, 80295-37-0, 80295-38-1
Jelic-Ivanovic, Z.; Department of Biochemistry, Pharmaceutical Faculty, Dr Subotica 8, PO Box 146,
© Copyright 2017 Elsevier B.V., All rights reserved.